Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods of improving spinal fusion with abavatide

A technology of abaloparatide and spine, applied in the field of enhancing spinal fusion, promoting rehabilitation after spinal surgery, and promoting bone formation

Pending Publication Date: 2022-04-15
RADIUS HEALTH INC
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] In patients with spinal fractures, deformities, or spinal instability, there remains an unmet need for agents that enhance spinal fusion and promote bone formation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods of improving spinal fusion with abavatide
  • Methods of improving spinal fusion with abavatide
  • Methods of improving spinal fusion with abavatide

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0058] The data presented in Example 1 contained excellent inter-observer and inter-modality concordance in fusion assessments. It is also noteworthy that the positive effect was achieved with a relatively modest dose of abaloparatide, which represents a significant improvement in its approved clinical dose compared to the dose of teripatide used in most rat spinal fusion studies. Substantially lower multiple. When dosed as low as 5 μg / kg / d, abaloparatide increases spinal BMD and promotes fracture bridging and callus strength in rats.

Embodiment 2

[0059] The data presented in Example 2 show that acceptable rates of spinal fusion were achieved in all Spinal Arthrodesis Model rabbits, with a success rate of 45% (5 / 11) in the control group. Across all metrics studied, better outcomes for spinal fusion surgery were observed in the group of rabbits given abaloparatide. A statistically significantly higher number of spines were determined (by MAF) to be acceptably fused. Larger and stronger fusion masses were also identified in abaloparatide-treated rabbits. Abaloparatide successfully improves the outcome of spinal fusion surgery in a large animal model (rabbit).

[0060] The following examples are provided to better illustrate the claimed method and should not be construed as limiting the scope of the method provided by the present invention. Where specific materials are mentioned, they are for purposes of illustration only and are not intended to be limiting of the invention. Those skilled in the art may develop equivale...

Embodiment

[0062] Example 1: Abaloparatide Enhances Spinal Fusion in a Rat Posterolateral Fusion Model

[0063]Data presented herein demonstrate that abaloparatide enhances spinal fusion in a rat posterolateral model (PLF) and a rabbit spinal arthrodesis model. Due to the positive effect of PTHR1 activation on spinal fusion observed in several studies and the potentially favorable overall pharmacodynamic profile of ABL with increased bone formation and minimal bone resorption, the efficacy of ABL in spinal fusion was investigated. ABL use had positive early effects on fusion mass structure in rats undergoing non-instrumented PLF.

[0064] The aim of this study was to evaluate the in vivo performance of daily injections of ABL20 (20 μg / kg) compared to saline controls in an established rat model of posterolateral fusion. Thirty-two 10-week-old male rats underwent posterolateral spinal surgery. A dorsal midline skin incision was made from L1 to the sacrum, followed by dissection of fascia...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Methods of enhancing spinal fusion and bone formation in patients with spinal fractures, deformity, or spinal instability are provided. The method comprises administering (e.g., subcutaneously or transdermally) a therapeutically effective amount of abavatide to the patient. In one aspect, the present invention provides a method of enhancing spinal fusion comprising administering to a patient suffering from a spinal fracture a therapeutically effective amount of abapalotide such that spinal fusion is enhanced in the patient.

Description

[0001] Cross References to Related Applications [0002] This application claims priority to U.S. Provisional Patent Application 62 / 899,633, filed September 12, 2019, the contents of which are incorporated by reference in their entirety, including the drawings. [0003] sequence listing [0004] This application incorporates by reference the Sequence Listing contained in the ASCII text file created on September 8, 2020, named R105231 1200PCT.txt, 4KB in size, and filed concurrently therewith. Background technique [0005] Spinal fusion is often an effective treatment for fractures, deformities, or instability in the spine to relieve pain and stabilize the spine. The number of spinal fusion discharges has increased significantly to >400K per year. However, complications such as nonunion and hardware failure are common, and to date no systematically administered drug has been approved to improve the outcome of spinal fusion surgery. [0006] In patients with spinal fractur...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61B17/00A61B17/20A61K33/06A61K33/30
CPCA61K38/29A61F2/4601A61F2/28A61F2002/2817A61P19/08A61P41/00A61P19/00
Inventor B·K·M·曼斯塔特B·米特拉卡
Owner RADIUS HEALTH INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com